Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Viewpoint - Exelixis is a commercial-stage, oncology-focused biotech company that has successfully established its first franchise with cabozantinib and aims to expand its pipeline of franchises [1]. Group 1 - The company has been operational for a significant period and believes it has reached a pivotal point in building its franchises [1]. - Exelixis held an R&D Day in December to discuss strategies for developing a pipeline of franchises and the multi-dimensional approach to franchise building [2].